Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 12/20 | 0.83 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | RXRB | P28702 | 1/20 | 0.44 |
| ▸ | RXRG | P48443 | 1/20 | 0.44 |
| ▸ | TTR | P02766 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3108130 | 0.91 | RBP4 (1.00) | RBP4NPSR1TTRHTR7 | |
| SCHEMBL3103394 | 0.89 | RBP4 (0.71) | RBP4NPSR1KDM4EALDH1A1GAA | |
| SCHEMBL3096133 | 0.88 | RBP4 (0.87) | RBP4NPSR1KDM4EALDH1A1GAA | |
| SCHEMBL18404577 | 0.88 | RBP4 (0.65) | RBP4KDM4EALDH1A1GAARXRA | |
| SCHEMBL3107397 | 0.86 | RBP4 (1.00) | RBP4TTR | |
| SCHEMBL3105954 | 0.86 | RBP4 (0.64) | RBP4NPSR1KDM4EALDH1A1GAA | |
| SCHEMBL3100388 | 0.86 | RBP4 (0.70) | RBP4NPSR1KDM4EALDH1A1GAA | |
| SCHEMBL3112227 | 0.85 | RBP4 (0.65) | RBP4NPSR1KDM4EALDH1A1GAA | |
| SCHEMBL3108209 | 0.84 | RBP4 (0.78) | RBP4NPSR1KDM4EALDH1A1GAA | |
| SCHEMBL13034523 | 0.83 | RBP4 (0.65) | RBP4NPSR1KDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250241902-A1 | METHODS, COMPOSITIONS AND SYSTEMS FOR EVALUATION OF VISUAL FUNCTION | BELITE BIO INC (US) | 2025-07-31 | — | — | US | claimed |
| CN-120129485-A | Methods, compositions, and systems for assessing visual function | 英属开曼群岛商倍亮生物有限公司 | 2025-06-10 | — | — | CN | claimed |
| EP-4507566-A1 | METHODS, COMPOSITIONS AND SYSTEMS FOR EVALUATION OF VISUAL FUNCTION | Belite Bio, Inc (US) | 2025-02-19 | — | — | EP | claimed |
| US-20240248099-A1 | BIOMARKERS FOR AGE-RELATED MACULAR DEGENERATION | BELITE BIO, LLC | 2024-07-25 | — | — | US | claimed |
| EP-4340701-A1 | BIOMARKERS FOR AGE-RELATED MACULAR DEGENERATION | Belite Bio, LLC (US) | 2024-03-27 | — | — | EP | claimed |
| CN-117440774-A | Biomarkers of age-related macular degeneration | 倍亮生物有限责任公司 | 2024-01-23 | — | — | CN | claimed |
| WO-2023200766-A1 | METHODS, COMPOSITIONS AND SYSTEMS FOR EVALUATION OF VISUAL FUNCTION | BELITE BIO, INC (US) | 2023-10-19 | — | — | WO | claimed |
| WO-2022246238-A1 | BIOMARKERS FOR AGE-RELATED MACULAR DEGENERATION | BELITE BIO, LLC (US) | 2022-11-24 | — | — | WO | claimed |
| US-8586571-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-19 | — | — | US | claimed |
| US-20250241902-A1 | METHODS, COMPOSITIONS AND SYSTEMS FOR EVALUATION OF VISUAL FUNCTION | BELITE BIO INC (US) | 2025-07-31 | — | — | US | disclosed |
| CN-120129485-A | Methods, compositions, and systems for assessing visual function | 英属开曼群岛商倍亮生物有限公司 | 2025-06-10 | — | — | CN | disclosed |
| EP-4507566-A1 | METHODS, COMPOSITIONS AND SYSTEMS FOR EVALUATION OF VISUAL FUNCTION | Belite Bio, Inc (US) | 2025-02-19 | — | — | EP | disclosed |
| US-20240248099-A1 | BIOMARKERS FOR AGE-RELATED MACULAR DEGENERATION | BELITE BIO, LLC | 2024-07-25 | — | — | US | disclosed |
| EP-4340701-A1 | BIOMARKERS FOR AGE-RELATED MACULAR DEGENERATION | Belite Bio, LLC (US) | 2024-03-27 | — | — | EP | disclosed |
| US-8586571-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-19 | — | — | US | disclosed |
| US-8586571-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-19 | — | — | US | disclosed |
| US-20100292206-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-18 | — | — | US | disclosed |
| US-20100292206-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-18 | — | — | US | disclosed |
| US-20100292206-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-18 | — | — | US | disclosed |
| EP-2202223-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250241902-A1 | METHODS, COMPOSITIONS AND SYSTEMS FOR EVALUATION OF VISUAL FUNCTION | PDE6C, SERPINA6, PDE6H | RBP4 11/4885NPSR1 1300/4885KDM4E 4721/4885 |
| US-20240248099-A1 | BIOMARKERS FOR AGE-RELATED MACULAR DEGENERATION | AGER, RBP4, RBP1 | RBP4 2/4885NPSR1 4151/4885KDM4E 4694/4885 |
| US-20100292206-A1 | HETEROCYCLIC COMPOUND | RBP4, RBP1, RAVER1 | RBP4 1/4885NPSR1 3073/4885KDM4E 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.